{"id":"W2331278657","doi":"10.1097/00054725-201112002-00076","title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs disease","year":2011,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Mount Sinai Hospital; Robarts Clinical Trials; University of Calgary","funders":"","keywords":"Ustekinumab; Medicine; Crohn's disease; Placebo; Vedolizumab; Internal medicine; Multicenter study; Quality of life (healthcare); Health related quality of life; Crohn disease; Randomized controlled trial; Randomization; Gastroenterology; Disease; Infliximab; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002362271,0.001538623,0.002802731,0.000389915,0.0004712701,0.0007075524,0.0005492687,0.001078418,0.003533162],"category_scores_gemma":[0.001330664,0.000480425,0.001760394,0.0004133421,0.0004549792,0.0006625316,0.0005440455,0.002289516,0.0004542835],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000419887,"about_ca_system_score_gemma":0.0006963554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006421072,"about_ca_topic_score_gemma":0.001222318,"domain_scores_codex":[0.9992517,0.0003241121,0.00006142042,0.0001284465,0.0000903546,0.0001438395],"domain_scores_gemma":[0.9987738,0.0001810531,0.0003593256,0.00009429856,0.0001375669,0.0004539754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9388125,0.01854173,0.009633059,0.0004324022,0.001364636,0.00003982976,0.00008091601,0.0005498032,0.004989224,0.00003492223,0.001074029,0.02444713],"study_design_scores_gemma":[0.5458869,0.3221568,0.1254809,0.00004708936,0.00172564,0.00007920525,0.00004344877,0.0007112007,0.00200847,0.0001067511,0.001707121,0.00004651244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925318,0.001802818,0.0002480377,0.0001442947,0.00006158433,0.001653513,0.00235315,0.00004742585,0.001157395],"genre_scores_gemma":[0.989272,0.0009791886,0.0008321679,0.0002852244,0.0001368633,0.00290818,0.003615091,0.00001695743,0.001954229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003533162,"threshold_uncertainty_score":0.01249301,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03982583798018915,"score_gpt":0.2891135360094876,"score_spread":0.2492876980292984,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}